Valneva SE Plans Active Participation in Investor Conferences
Valneva SE, a prominent specialty vaccine company, has announced its participation in major investor conferences scheduled for June. As the company gears up for these events, it emphasizes the significance of engaging with potential investors and partners to showcase its cutting-edge developments in vaccine technology.
This effort aligns with Valneva's mission to advance solutions for global health risks through innovative vaccines. The company is well-known for its groundbreaking Lyme disease vaccine candidate, VLA15, which targets a condition that has affected many worldwide. Valneva has partnered with Pfizer for this initiative, and the partnership underscores a collective commitment to combating infectious diseases.
Key Topics and Presentations
Throughout the conferences, Valneva's management team is expected to discuss several critical topics that outline the company's vision and progress. Notably, the company's presentations will highlight their extensive portfolio of vaccine candidates. These discussions will delve into VLA15's pivotal Phase 3 trial, where preliminary data is anticipated toward the end of this year.
Investor Meetings Overview
For investors eager to connect with Valneva's leadership, one-on-one meetings will be facilitated at the following conferences:
Jefferies Global Healthcare Conference
The conference will feature a fireside chat and investor meetings. This event takes place on June 5, 2025, in New York. Attendees will have the opportunity to engage directly with senior management, discussing the latest developments and innovations at Valneva.
Goldman Sachs 46th Annual Global Healthcare Conference
Taking place on June 9, 2025, in Miami, FL, this conference will maintain a similar format of fireside chats and investor meetings. This gathering will further enable investors to explore Valneva's strategic direction and advancements.
Oddo BHF Nextcap Forum
On June 12, 2025, Valneva will participate virtually in the Oddo BHF Nextcap Forum. This unique format focuses exclusively on investor meetings, allowing deep dives into the company's pipeline and future prospects.
BNP Paribas SMID Cap Conference
Finally, Valneva will conclude its active month at the BNP Paribas SMID Cap Conference on June 18, 2025, in Paris. Here, Valneva's leadership will engage with investors to share insights on their growth strategies and ongoing vaccine developments.
About Valneva SE
Valneva SE stands at the forefront of vaccine innovation, committed to developing and providing vaccines for infectious diseases that currently lack adequate solutions. Their approach combines specialized knowledge with a goal of delivering first-, best-, and only-in-class vaccine products.
With several successful vaccines currently on the market, Valneva continues to invest in research and development to enhance its innovative pipeline. Among its assets are the only Lyme disease vaccine candidate in advanced clinical phases, collaborations with Pfizer, and leading candidates against other public health challenges such as Shigella and Zika virus. This continued focus on research and commercial growth positions Valneva as a key player in the vaccination landscape.
Frequently Asked Questions
What events will Valneva SE participate in June?
Valneva will take part in several investor conferences including Jefferies Global Healthcare Conference and Goldman Sachs Annual Global Healthcare Conference.
What is VLA15?
VLA15 is an advanced vaccine candidate targeting Lyme disease and is currently in a pivotal Phase 3 trial, underscoring Valneva's commitment to addressing public health needs.
How does Valneva plan to engage investors?
Valneva will hold one-on-one investor meetings and presentations to discuss their pipeline and recent developments with attendees at the conferences.
What are the key topics Valneva will cover?
Valneva will focus on their commercial stage vaccines and the innovative candidates in their portfolio during their presentations.
Who can investors contact for more information?
Investors seeking further information can reach out to Valneva's investor relations team for support and details regarding the events.
